Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Epilepsy and seizure classification

Repurposing dimethyl fumarate as an antiepileptogenic and disease-modifying treatment for drug-resistant epilepsy.

Sereen Sandouka; Prince Kumar Singh; Aseel Saadi; Rhoda Olowe Taiwo; Yara Sheeni; Taige Zhang; Larin Deeb; Michelle Guignet; Steve H White; Tawfeeq Shekh-Ahmad

Originally published in Journal of translational medicine · 2023-11-08

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Epilepsy affects over 65 million people worldwide and significantly burdens patients, caregivers, and society. Drug-resistant epilepsy occurs in approximately 30% of patients and growing evidence indicates that oxidative stress contributes to the development of such epilepsies. Activation of the Nrf2 pathway, which is involved in cellular defense, offers a potential strategy for reducing oxidative stress and epilepsy treatment. Dimethyl fumarate (DMF), an Nrf2 activator, exhibits antioxidant and anti-inflammatory effects and is used to treat multiple sclerosis. Methods The expression of Nrf2 and its related genes in vehicle or DMF treated rats were determined via RT-PCR and Western blot analysis. Neuronal cell death was evaluated by immunohistochemical staining. The effects of DMF in preventing the onset of epilepsy and modifying the disease were investigated in the kainic acid-induced status epilepticus model of temporal lobe epilepsy in rats. The open field, elevated plus maze and T-Maze spontaneous alteration tests were used for behavioral assessments.

Discussion

In the present investigation, we demonstrated that early and late treatment with the Nrf2 activator DMF is disease-modifying in the post-SE rat model of acquired epilepsy. One week of DMF treatment beginning two hours after SE onset activated Nrf2-associated genes, enhanced neuroprotection in the hippocampus, attenuated epileptogenesis progression, and reversed SE-induced behavioral changes in the open field and elevated plus maze.

Conclusions

Overall, the effects observed following DMF treatment suggest that Nrf2 is a promising therapeutic target for preventing or attenuating epileptogenesis and associated comorbidities of epilepsy. DMF increased the expression of the downstream Nrf2 genes NQO1 and HO-1, which is consistent with its known effects on the Nrf2 pathway and provides a potential mechanism by which it could exert its therapeutic effects in preclinical models of epilepsy.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?